January 22nd, 2017
•We present a biochemical and behavioral protocol to evaluate the efficacy of mitochondria-targeted water-soluble compounds for the treatment of Spinocerebellar ataxia type 1 (SCA1) and other cerebellar neurodegenerative diseases.
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved